CRNX vs INHD
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. INHD: High-growth industrial products company in early commercialization phase, reinvesting rapidly in inventory and operations with recent equity raises.
Side-by-side fundamentals
| Metric | CRNX | INHD | Edge |
|---|---|---|---|
| Price as of 2026-07-23 close | $83.65 | $39.49 | |
| Market cap as of 2026-07-24 | $8.9B | $179M | |
| PEG as of 2026-07-24 | -0.47 | n/a | |
| Net margin as of 2026-07-24 | -2747.2% | -86.8% | INHD higher |
| Gross margin as of 2026-07-24 | +86.0% | +2.1% | CRNX higher |
| Operating margin as of 2026-07-24 | -3020.3% | -83.6% | INHD higher |
| ROE as of 2026-07-24 | -44.0% | -13.5% | INHD higher |
| ROA as of 2026-07-24 | -39.6% | -13.3% | INHD higher |
| Debt / equity as of 2026-07-24 | 0.00 | 0.00 | CRNX lower |
| Revenue growth (YoY) as of 2026-07-24 | +2277.5% | +276.4% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | -14.2% | |
| Beta as of 2026-07-24 | 0.10 | -12.11 | |
| 1-year return as of 2026-07-23 close | +174.8% | +73.2% | CRNX higher |
Fundamentals: Finnhub, as of 2026-07-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-23.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.